Literature DB >> 15023151

New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis.

Olaf Heisel1, Rochelle Heisel, Robert Balshaw, Paul Keown.   

Abstract

New onset diabetes mellitus (NODM) is a serious complication of transplantation. This meta-analysis evaluates the reported incidence of NODM after solid organ transplantation in patients receiving CNI treatment. Databases from January 1992 to April 2002 were searched. Fifty-six publications providing NODM incidence data were reviewed. Sixteen prospective, randomized comparative studies providing information on incidence of insulin-dependent diabetes mellitus (IDDM) were subjected to meta-analysis. New onset diabetes mellitus was reported in 13.4% of patients after solid organ transplantation, with a higher incidence in patients receiving tacrolimus than cyclosporine (16.6% vs. 9.8%). This trend was observed across renal, liver, heart and lung transplant groups. Meta-analysis of 16 studies included patients receiving either tacrolimus (n=1636) or cyclosporine (n=1407). The incidence of IDDM was significantly higher among tacrolimus-treated patients (10.4% vs. 4.5%, p<0.00001), an effect observed in renal (9.8% vs. 2.7% p<0.00001) and nonrenal (11.1% vs. 6.2%; p<0.003) groups, and among patients receiving equal doses of concomitant medication in both treatment arms (12.0% vs. 3.0%; p<0.00001). The reported incidence of NODM during the past decade was significantly higher among patients receiving tacrolimus than cyclosporine. These data provide a quantitative foundation for studies designed to reduce the rates of NODM following solid organ transplantation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023151     DOI: 10.1046/j.1600-6143.2003.00372.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  99 in total

1.  Association of metabolic syndrome with development of new-onset diabetes after transplantation.

Authors:  Nathaniel D Bayer; Philip T Cochetti; Mysore S Anil Kumar; Valerie Teal; Yonghong Huan; Cataldo Doria; Roy D Bloom; Sylvia E Rosas
Journal:  Transplantation       Date:  2010-10-27       Impact factor: 4.939

2.  Metabolic Syndrome Components After Pediatric Liver Transplantation: Prevalence and the Impact of Obesity and Immunosuppression.

Authors:  E R Perito; R H Lustig; P Rosenthal
Journal:  Am J Transplant       Date:  2016-03-17       Impact factor: 8.086

Review 3.  Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data.

Authors:  Angela C Webster; Rebecca C Woodroffe; Rod S Taylor; Jeremy R Chapman; Jonathan C Craig
Journal:  BMJ       Date:  2005-09-12

Review 4.  Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner.

Authors:  Daniel Benten; Katharina Staufer; Martina Sterneck
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-11-25

Review 5.  Posttransplant diabetes and hypertension: pathophysiologic insights and therapeutic rationale.

Authors:  Moro O Salifu; Fasika Tedla; Serhat Aytug; Amir Hayat; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

6.  Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data.

Authors:  L S Vest; F M Koraishy; Z Zhang; N N Lam; M A Schnitzler; V R Dharnidharka; D Axelrod; A S Naik; T A Alhamad; B L Kasiske; G P Hess; K L Lentine
Journal:  Clin Transplant       Date:  2018-06-29       Impact factor: 2.863

Review 7.  New frontiers in immunosuppression.

Authors:  Luke J Benvenuto; Michaela R Anderson; Selim M Arcasoy
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

8.  Extracellular factors and immunosuppressive drugs influencing insulin secretion of murine islets.

Authors:  V J Auer; E Janas; V Ninichuk; E Eppler; T S Weiss; S Kirchner; A M Otto; M J Stangl
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

9.  CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients.

Authors:  Daohua Shi; Tiancheng Xie; Jie Deng; Peiguang Niu; Weizhen Wu
Journal:  Eur J Clin Pharmacol       Date:  2018-03-15       Impact factor: 2.953

Review 10.  Cardiac allograft vasculopathy and insulin resistance--hope for new therapeutic targets.

Authors:  Luciano Potena; Hannah A Valantine
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.